Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
Ontology highlight
ABSTRACT: The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy
SUBMITTER: Wouters OJ
PROVIDER: S-EPMC7906643 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA